Clinical Trials
6 trialsNCT03875287 2026-01-12
Dose-Escalation Study of E7727, an Oral Cytidine Deaminase Inhibitor With Oral Decitabine in Subjects With Solid Tumors
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Active not recruiting
NCT03233724 2023-05-31
Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal Carcinomas
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT00037817 2019-09-30
Phase I Study of Gene Induction Mediated by Sequential Decitabine/Depsipeptide Infusion With or Without Concurrent Celecoxib in Subjects With Pulmonary and Pleural Malignancies
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT04076137 2019-09-03
Targeted T-cell Therapy in Solid Tumors
Benhealth Biopharmaceutical (Shenzhen) Co., Ltd.
Phase EARLY_PHASE1 Unknown
NCT00019825 2015-04-29
Decitabine in Treating Patients With Unresectable Lung or Esophageal Cancer or Malignant Mesothelioma of the Pleura
National Cancer Institute (NCI)
Phase 1 Completed
NCT00701298 2014-02-24
Decitabine With or Without Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Solid Tumors
National Cancer Institute (NCI)
Phase 1 Terminated